TrialLeukemia & lymphoma2021

Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma.

Wyndham H Wilson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.